GeneHealth - Your precision medicine

Nonketotic Hyperglycinaemia

Disease Details

Family Health Simplified

Buy Membership

Description: Nonketotic hyperglycinemia (NKH) is a rare, inherited metabolic disorder characterized by abnormally high levels of the amino acid glycine in the body, leading to severe neurological symptoms.
Type: Nonketotic hyperglycinemia (NKH) is an inherited metabolic disorder. It follows an autosomal recessive pattern of genetic transmission.
Signs And Symptoms: Nonketotic hyperglycinemia (NKH), also known as glycine encephalopathy, is a rare inherited metabolic disorder characterized by an excess amount of glycine in the body. This is due to a defect in the glycine cleavage system. The major signs and symptoms include:

- Neurological: Seizures, lethargy, hypotonia (low muscle tone), poor feeding, and apnea (breathing difficulties) in neonates.
- Developmental: Severe developmental delay, intellectual disability, and failure to achieve developmental milestones.
- Physical: In some cases, physical malformations or abnormal muscle movements (e.g., myoclonic jerks) may be observed.

NKH can present in different forms, ranging from a severe neonatal form to milder, late-onset forms. The severity and combination of symptoms can vary significantly among individuals.
Prognosis: Nonketotic hyperglycinemia (NKH) is a rare genetic disorder characterized by an accumulation of glycine in the body due to a defect in the enzyme system responsible for breaking down the amino acid glycine. The prognosis for NKH varies depending on the severity of the condition.

Neonatal severe form:
- Prognosis tends to be poor.
- Many affected infants experience severe neurological deficits, including profound intellectual disability, seizures, and muscle hypotonia.
- Lifespan is often significantly reduced, with many affected individuals not surviving beyond early childhood.

Attenuated (milder) form:
- Prognosis is somewhat better but still involves significant challenges.
- Individuals may experience developmental delays, intellectual disabilities, and less severe forms of seizures.
- Lifespan can vary; some individuals may live into adolescence or adulthood.

The severity of symptoms and outcomes can vary widely among individuals, making it crucial for each case to be managed by a team of specialized healthcare providers for the best possible outcome.
Onset: Nonketotic hyperglycinemia (NKH) typically presents in the neonatal period, often within the first few days of life. Newborns may exhibit symptoms such as poor feeding, lethargy, weak muscle tone, and seizures.
Prevalence: The prevalence of nonketotic hyperglycinaemia (NKH) is estimated to be quite rare, occurring in approximately 1 in 60,000 to 1 in 252,000 live births globally. The exact prevalence can vary depending on the population and geographic region.
Epidemiology: Nonketotic hyperglycinemia (NKH) is a rare autosomal recessive metabolic disorder characterized by an excess of glycine due to a defect in the glycine cleavage system. Its incidence is estimated to be approximately 1 in 60,000 live births. The condition occurs with equal frequency among males and females and has been reported in various ethnic groups worldwide.
Intractability: Nonketotic hyperglycinemia (NKH) is generally considered intractable because it is a genetic disorder characterized by a defect in the glycine cleavage system, leading to an accumulation of glycine in the body. This condition often results in severe neurological symptoms, including developmental delay, seizures, and hypotonia. Current treatment options are limited and focus primarily on managing symptoms rather than curing the disease. Therefore, NKH is typically chronic and refractory to standard medical interventions.
Disease Severity: Nonketotic hyperglycinemia (NKH) is a rare genetic disorder characterized by an accumulation of glycine in the body due to a defect in the enzyme system responsible for breaking down glycine. The severity of the disease can vary but is generally severe and life-threatening. Symptoms typically appear shortly after birth and can include lethargy, weak muscle tone (hypotonia), seizures, and developmental delays. Prognosis is often poor, with many affected individuals experiencing significant neurological impairment.
Healthcare Professionals: Disease Ontology ID - DOID:9268
Pathophysiology: The pathophysiology of nonketotic hyperglycinemia (NKH) involves a defect in the glycine cleavage system, particularly due to mutations in the genes encoding the P, T, H, or L proteins of the glycine cleavage enzyme complex. This leads to an inability to properly metabolize the amino acid glycine, resulting in its accumulation in body tissues and fluids, including the brain. Elevated glycine levels disrupt normal neurological function, causing severe symptoms such as seizures, hypotonia, and developmental delay.
Carrier Status: Carrier status for nonketotic hyperglycinemia (NKH) is typically autosomal recessive. This means that an individual must inherit two copies of the mutated gene, one from each parent, to exhibit symptoms of the disease. Carriers, who have only one copy of the mutated gene and one normal gene, usually do not show symptoms but can pass the mutated gene to their offspring.
Mechanism: Nonketotic hyperglycinemia (NKH) is a rare genetic disorder characterized by an accumulation of glycine in the body due to a defect in the glycine cleavage system (GCS). The GCS is a mitochondrial enzyme complex responsible for the breakdown of glycine into carbon dioxide and ammonia.

**Mechanism:**
1. **Glycine Accumulation:** NKH results from mutations in the genes encoding components of the GCS, leading to an ineffective breakdown of glycine.
2. **Elevated Glycine Levels:** High levels of glycine accumulate in the blood, urine, and particularly the cerebrospinal fluid.
3. **Neurological Impact:** The excessive glycine inhibits normal neural functioning, leading to symptoms that include severe neurological impairments, seizures, and developmental delays.

**Molecular Mechanisms:**
1. **Genetic Mutations:** NKH is most commonly linked to mutations in the GLDC (glycine decarboxylase), AMT (aminomethyltransferase), or GCSH (glycine cleavage system protein H) genes.
2. **Enzymatic Dysfunction:** These mutations cause partial or complete loss of function of the respective proteins, disrupting the normal catalytic activity of the GCS.
3. **Enzyme Complex Impairment:** The GCS comprises four protein components: P-protein (GLDC), T-protein (AMT), H-protein (GCSH), and L-protein (dihydrolipoamide dehydrogenase). Mutations in any of these components lead to inefficient glycine cleavage and subsequent biochemical and metabolic disturbances.

By impeding glycine breakdown, these molecular disruptions result in the accumulation of glycine, which profoundly affects the central nervous system, manifesting in the clinical symptoms of NKH.
Treatment: Nonketotic hyperglycinemia (NKH) is a rare genetic disorder characterized by an excess of the amino acid glycine in the body, particularly in the brain. The treatment for NKH primarily aims to manage symptoms and may include:

1. **Sodium benzoate**: Used to help reduce glycine levels in the blood.
2. **Dextromethorphan**: An NMDA receptor antagonist, which may help reduce neurological symptoms by blocking glycine receptors.
3. **Antiepileptic drugs**: To manage seizures that are common in patients with NKH.
4. **Aggressive supportive care**: Often necessary, including respiratory support, nutritional support, and management of complications such as infections.

Despite these treatments, prognosis for NKH is often poor, and there is currently no cure for the disorder. Early diagnosis and intervention can improve management of symptoms and quality of life.
Compassionate Use Treatment: Nonketotic hyperglycinemia (NKH) is a rare metabolic disorder characterized by an accumulation of glycine in the body due to a defect in the glycine cleavage system. Currently, there is no cure for NKH, and treatment options primarily aim to manage symptoms and reduce glycine levels. For compassionate use and off-label or experimental treatments, the following can be considered:

1. **Sodium Benzoate**: This compound helps decrease glycine levels by promoting its excretion in the urine. It is often used in conjunction with other therapies.

2. **Dextromethorphan**: An NMDA receptor antagonist that may reduce the neurotoxic effects of high glycine levels in the brain; used off-label in NKH.

3. **Ketogenic Diet**: Though not standard, some patients have shown benefits from a ketogenic diet, which may help in managing seizures and other neurological symptoms.

4. **NMDA Receptor Antagonists**: Other NMDA receptor antagonists, beyond dextromethorphan, are being explored for their potential benefits.

5. **Experimental Gene Therapy**: Still in very early stages, gene therapy aims to correct the underlying genetic defect in the glycine cleavage system.

Always consult with a healthcare professional before considering or starting any new treatment.
Lifestyle Recommendations: Nonketotic hyperglycinemia (NKH) is a rare, inherited metabolic disorder characterized by an inability to properly break down the amino acid glycine. Lifestyle recommendations for individuals with NKH typically focus on supportive care and symptom management, as there is no cure for the condition. These recommendations may include:

1. **Medical Supervision:** Regular follow-ups with a metabolic specialist, neurologist, and other healthcare providers to monitor and manage symptoms.
2. **Dietary Management:** A diet low in protein may be recommended to reduce glycine levels in the body. This should be done under the guidance of a metabolic dietitian.
3. **Seizure Management:** Anticonvulsant medications may be prescribed to control seizures, which are common in NKH patients.
4. **Developmental Support:** Early intervention programs, including physical therapy, occupational therapy, and speech therapy, can help manage developmental delays and improve quality of life.
5. **Supportive Therapies:** Use of respiratory support if needed due to breathing difficulties, and managing feeding difficulties which might require the use of feeding tubes.
6. **Family Support:** Counseling and support groups for families to help them cope with the emotional and practical challenges of caring for someone with NKH.
Medication: Nonketotic hyperglycinemia (NKH) is a rare genetic disorder characterized by an accumulation of glycine in the body due to a defect in the glycine cleavage system. Treatment often involves a combination of dietary management and medications to reduce glycine levels and manage symptoms. Common medications include:

1. **Sodium benzoate**: Helps reduce glycine levels by promoting its excretion in urine.
2. **Dextromethorphan**: Can help manage neurological symptoms by modulating N-methyl-D-aspartate (NMDA) receptors.
3. **Ketamine**: Sometimes used for its NMDA receptor antagonistic properties in severe cases.

Regular follow-up with a metabolic specialist is essential for managing the condition effectively.
Repurposable Drugs: Currently, there are no widely recognized repurposable drugs specifically for nonketotic hyperglycinemia (NKH). Standard treatment typically involves managing symptoms with sodium benzoate to reduce glycine levels, and using dextromethorphan to block NMDA receptors. Research is ongoing, so it's essential to consult recent studies or specialized sources for potential new developments.
Metabolites: Nonketotic hyperglycinemia (NKH) primarily involves the metabolite glycine. In NKH, there is an abnormally high accumulation of glycine in the body, particularly in the brain and other tissues. This excessive glycine interferes with normal neurological functions and development.
Nutraceuticals: Nonketotic hyperglycinemia (NKH) is a rare metabolic disorder characterized by an accumulation of glycine in the body's tissues and fluids due to a defect in the glycine cleavage system. Currently, there is no cure for NKH, and traditional treatments focus on managing symptoms and reducing glycine levels.

Regarding nutraceuticals, there is limited research supporting their use in managing NKH. Nutraceuticals typically refer to food-derived products with potential health benefits. Given NKH is a genetic and metabolic condition, conventional approaches, including medications like sodium benzoate to help reduce glycine levels, are more commonly used.

It's essential to consult healthcare professionals before considering any alternative treatments, including nutraceuticals, for NKH management.
Peptides: Nonketotic hyperglycinemia (NKH) is a rare inherited metabolic disorder characterized by an accumulation of glycine in the body due to a defect in the glycine cleavage system. Peptides are short chains of amino acids linked by peptide bonds, and in the context of NKH, glycine, as an amino acid, accumulates to toxic levels due to the faulty enzyme complex.

As for "nan," if you are referring to the abbreviation commonly used as "not a number," it's unclear within the context of NKH as the term doesn't provide specific relevant information related to the condition. If you meant something else by “nan,” further clarification would be helpful.